A recent study identified PDHA1 as a mediator of ferroptosis resistance in prostate cancer via upregulation of AIFM2, revealing a potential mechanism by which tumors evade lipid‑peroxidation‑driven cell death. The research maps a pathway that could be targeted to sensitize resistant cancers to ferroptosis‑based therapies. Authors suggest that inhibiting PDHA1 or intervening downstream at AIFM2 may restore ferroptotic susceptibility in metastatic or treatment‑refractory prostate tumors; translational work will be required to validate targets in vivo and evaluate safety.